Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Charles J who wrote (4120)	4/3/1998 4:01:00 PM
From: Bradpalm1	Respond to of 34592

Charles J, Despite these releases, SciClone's Zadaxin (thymosin alpha 1) still looks like a product waiting for a disease to treat. I've looked at some of these Phase II and III studies and the results, thus far, aren't really impressive. Further, interferon and ribaviran appear to be more efficaceous than the results of interferon with Zadaxin for treatment of Hepatitis C. The world is still anxiously awaiting a good treatment for Hepatitis B and C as well as liver cancer. I don't think that SciClones Zadaxin will be the answer they're looking for. Bradpalm1

To: Charles J who wrote (4120)	4/13/1998 3:23:00 PM
From: Charles J	Read Replies (2) \| Respond to of 34592

Dakin Securities Starts Coverage of SciClone With a 'Buy' Recommendation SAN FRANCISCO, April 13 /PRNewswire/ -- Dakin Securities analyst Jim McCamant initiated coverage of SciClone Pharmaceuticals (Nasdaq: SCLN - news) with a ''buy'' recommendation. Mr. McCamant set an 18-month price target of $10 on the stock, which closed Wednesday at $3.375. He cited growing sales of SciClone's lead hepatitis product, ZADAXIN(R) thymosin alpha 1, its partnership in Japan with Schering-Plough [NYSE:SGP - news] K.K., the company's lead cystic fibrosis product, CPX, and stronger management for the recommendation.